Samarium-153

Samarium-153 (Sm-153) is a radioisotope used in metabolic radiotherapy for the treatment of pain from bone metastases. It is produced in nuclear reactors, by neutron irradiation of samarium-152 (Sm-152 Sm2O3).

Samarium-153 decays by emitting both beta minus particles and gamma photons with a characteristic gamma peak of 103.2 KeV; it has a physical half-life time of 1.93 days. The carrier molecule used is the ethylene diamine tetramethylene phosphonate acid (EDTMP), a chelator osteotropic tetraphosphonate. The radiopharmaceutical Sm-153 EDTMP (dose: 37 MBq/Kg) shows a biodistribution similar to that of technetium-99m methylene diphosphonate (Tc-99m MDP). The gamma (photons) component also allows the use of the radiotracer for nuclear medical imaging (follow-up).

Imaging technology

Article information

rID: 74414
System: Oncology
Synonyms or Alternate Spellings:
  • Sm-153
  • Sm-153 EDTMP
  • Samarium-153 EDTMP

ADVERTISEMENT: Supporters see fewers/no ads

Cases and figures

  • Skeletal metastases
    Drag here to reorder.
  • Updating… Please wait.

     Unable to process the form. Check for errors and try again.

     Thank you for updating your details.